The currently postulated mechanisms explaining the role of RBMS3 in the progression of breast cancer include involvement in the epithelial–mesenchymal transition (EMT) by inhibiting the Wnt/β-catenin signaling pathway and other EMT-related transcription factors, such as TWIST1 or PRRX1 [12,17,19,20]. This evidence concerns the gene PRRX1 and breast cancer.